Logo

MorphoSys Terminates Merger Talks

Oct 23, 2002

NEW YORK, Oct. 23-The German synthetic antibody firm MorphoSys said today that it had terminated merger talks with British Biotech, a publicly owned drug development company.

 

MorphoSys said that it did not expect to realize any equity-based transactions or partnerships this year, and reduced its year-end cash position guidance to roughly € 15 million.  The company held cash and cash equivalents of € 568,987 as of June 30, 2002.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.